Symbiotec Pharmalab Q1FY27 Revenue at ₹218.2 Cr, PAT ₹14.1 Cr
Symbiotec Pharmalab reported Q1FY27 consolidated revenue of ₹218.2 crore, up from ₹203.2 crore in Q1FY26. Consolidated PAT decreased to ₹14.1 crore from ₹29.9 crore. The API business saw a 6% sales growth. The company filed its first ANDA for a DCV product and has significant capex planned for new revenue streams.
The decline in PAT and EBIDTA, despite revenue growth in the core API segment, indicates potential short-term pressure. However, successful regulatory filings and planned capex for new businesses suggest potential for future growth, making the impact medium-term.
While the API business showed steady growth and regulatory milestones were achieved, the consolidated PAT and EBIDTA declined year-on-year due to investments in new, yet-to-be-revenue-generating businesses. This presents a mixed financial picture.
Symbiotec Pharmalab Limited announced its financial results for the first quarter ended June 30, 2026. The company reported consolidated revenues of ₹218.2 crore, a marginal increase from ₹203.2 crore in the same quarter last year. However, consolidated Earnings Before Interest, Taxes, Depreciation, and Amortization (EBIDTA) saw a decline to ₹45.2 crore from ₹58.0 crore in Q1FY26, and Consolidated Profit After Tax (PAT) dropped to ₹14.1 crore from ₹29.9 crore year-on-year. The API business demonstrated steady performance with operating revenue of ₹215.3 crore, up from ₹203.2 crore in Q1FY26, and API EBIDTA margins remained stable at approximately 30%. The company highlighted that the drag in consolidated EBIDTA and PAT was due to expenses from new businesses not yet generating revenue, with revenue generation from these new ventures expected to commence within the next 6-12 months. Key operational highlights include a 6% year-on-year sales growth in APIs. Symbiotec successfully completed four major regulatory audits, including EUGMP audits for its Rau and Pithampur plants and a USFDA audit at the Rau plant, receiving approval certifications and EIRs where applicable. In Complex Injectables, a licensing agreement for two DCV products in the US is at an advanced stage, and the company filed its first ANDA for a DCV product in September 2026. For Biotech-CDMO Services, the company has onboarded customers and secured take-or-pay agreements with US and Europe-based Alternate Protein players. The company has a total gross capex of approximately ₹1,666 crore estimated by the end of FY27, with ₹1,000 crore invested in new revenue-generating businesses. As of June 30, 2026, Net Debt was approximately ₹398 crore, which reduced to approximately ₹326 crore after IPO proceeds as of September 20, 2026. Mr. Anil Satwani, Chairman & Managing Director, noted that the API business delivered steady revenue and EBITDA growth, enabling investments in new growth engines. He also mentioned progress in Complex Injectables with the first ANDA filing and deepening pipeline, and widening engagement in Biotech-CDMO Services with predictable, recurring revenue streams.
The company plans to commence revenue generation from new capacities within the next 6-12 months and has invested approximately ₹68 crore in gross capex during Q1FY27. The filing of the second ANDA for a DCV product is scheduled for early Q4FY27, and regulatory approval filing for the Insulin Drug Substance is expected in Q4FY27.
What to do with a filing like this
Symbiotec Pharmalab Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Symbiotec Pharmalab Limited. Read the original for the full detail.